Abstract: The present invention relates to IgE epitope-like peptides which have ability to bind to allergen specific IgE paratopes. Said allergen specific IgEs are bound to effector cells of allergic patients. The IgE epitope-like peptides of the invention cover the paratopes of said IgE bound on effector cells, prevent biding of causative allergen on said IgE on effector cells, and thereby prevent degranulation and secretion of mediators of allergic inflammation from effector cells, after contact with the causative allergen. The present invention relates to the methods of using such IgE epitope-like peptides for therapy of allergic reaction. Said allergic reaction is caused by exposure to the causative allergen.

Abstract: The present invention relates to ligand that may be a peptide compound as well as peptoid or retro-inverso analogues thereof with binding affinity for the Fc region of immunoglobulins. The invention further relates to the application of such peptides and variants thereof for purification of immunoglobulins on the basis of affinity chromatography, non-covalent antibody labelling, antibody detection or immobilization of antibodies to solid support.

Abstract: The present invention relates to microorganisms that express, or have attached to their surface, a TNF? binding polypeptide. Peptides expressed or attached on the surface of microorganism are more resistant to chemical and enzymatic degradation in the gastrointestinal tract. Such microorganisms are capable of binding TNF? and therefore reducing the content of free TNF? and alleviating its pro-inflammatory effects in the gut. The invention also relates to the use of such microorganisms as medicament in the treatment of inflammatory bowel disease.

Abstract: The present invention relates to microorganisms that express, or have attached to their surface, a TNF? binding polypeptide. Peptides expressed or attached on the surface of microorganism are more resistant to chemical and enzymatic degradation in the gastrointestinal tract. Such microorganisms are capable of binding TNF? and therefore reducing the content of free TNF? and alleviating its pro-inflammatory effects in the gut. The invention also relates to the use of such microorganisms as medicament in the treatment of inflammatory bowel disease.